Perkin-Elmer To Introduce New Instrument Based On Breakthrough DNA Analysis Technology

May 09, 1998

NORWALK, Conn., May 9, 1998 -- The Perkin-Elmer Corporation (NYSE: PKN) announced today that it was nearing the end of development of a breakthrough DNA analysis technology that should enable the generation of sequencing data at an ultra-high throughput level. The Company is designing the 3700 DNA Analyzer to provide the catalyst for a major new genomics initiative. While production shipments are scheduled for the first quarter of calendar year 1999, Perkin-Elmer expects to shortly announce an early access program for customers interested in becoming test sites for the instrument late in calendar year 1998.

As reported in a separate news announcement made today, Perkin-Elmer, genomics pioneer Dr. J. Craig Venter, and The Institute for Genomic Research (TIGR) have signed letters of intent relating to the formation by Perkin-Elmer and Dr. Venter of a new genomics company which will be a beta test site for the instrument. The new company's strategy will be centered on a plan to substantially complete the sequencing of the human genome in three years.

The 3700 DNA Analyzer, to be priced at approximately $300,000, is the first model of a new product category in DNA sequencing and genetic analysis that is designed to enable applications requiring tens of thousands of samples produced weekly. This production-scale instrument will be marketed with the current 377 and 310 instruments as part of the ABI PRISM family of genetic analysis instruments. The 3700 DNA Analyzer, under development at the Applied Biosystems Division of Perkin-Elmer, combines proven capillary electrophoresis hardware and separation polymer chemistry, with new detection technology and automation.

The 3700 DNA Analyzer is designed for customers who require: The Perkin-Elmer Corporation is a leading supplier of systems for life science research and related applications. It develops, manufactures, and markets life science systems and analytical instruments used in markets such as pharmaceutical, biotechnology, environmental testing, foods, agriculture, and chemical manufacturing. Headquartered in Connecticut, Perkin-Elmer had revenues of nearly $1.4 billion in fiscal 1997 and employs more than 6,000 people worldwide.

Certain statements in this press release and its attachments are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "anticipate," "intend," "should," "planned," "estimated," "potential," and "will" among others. These forward-looking statements are based on Perkin-Elmer's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Perkin-Elmer notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Perkin-Elmer's and the new company's businesses include but are not limited to (1) complexity and uncertainty regarding the development of new high-technology products; (2) loss of market share through competition; (3) introduction of competing products or technologies by other companies; (4) pricing pressures from competitors and/or customers; (5) changes in the life science or analytical instrument industries; (6) changes in the pharmaceutical, environmental, research, or chemical markets; (7) variable government funding in key geographical regions; (8) Perkin-Elmer's and the new company's ability to protect proprietary information and technology or to obtain necessary licenses on commercially reasonable terms; (9) the loss of key employees; (10) fluctuations in foreign currency exchange rates; and (11) other factors that might be described from time to time in Perkin-Elmer's filings with the Securities and Exchange Commission.

Noonan/Russo Communications

Related Human Genome Articles from Brightsurf:

240 mammals help us understand the human genome
A large international consortium led by scientists at Uppsala University and the Broad Institute of MIT and Harvard has sequenced the genome of 130 mammals and analysed the data together with 110 existing genomes to allow scientist to identify which are the important positions in the DNA.

The National Human Genome Research Institute publishes new vision for human genomics
The National Human Genome Research Institute this week published its 'Strategic vision for improving human health at The Forefront of Genomics' in the journal Nature.

Interpreting the human genome's instruction manual
Berkeley Lab bioscientists are part of a nationwide research project, called ENCODE, that has generated a detailed atlas of the molecular elements that regulate our genes.

3-D shape of human genome essential for robust inflammatory response
The three-dimensional structure of the human genome is essential for providing a rapid and robust inflammatory response but is surprisingly not vital for reprogramming one cell type into another.

The genome of chimpanzees and gorillas could help to better understand human tumors
A new study by researchers from the Institute of Evolutionary Biology (IBE), a joint center of UPF and the Spanish National Research Council (CSIC), shows that, surprisingly, the distribution of mutations in human tumors is more similar to that of chimpanzees and gorillas than that of humans.

It's in our genome: Uncovering clues to longevity from human genetics
Researchers from Osaka University found that high blood pressure and obesity are the strongest factors reducing lifespan based on genetic and clinical information of 700,000 patients in the UK, Finland and Japan.

New limits to functional portion of human genome reported
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.

Synthesizing the human genome from scratch
For the past 15 years, synthetic biologists have been figuring out how to synthesize an organism's complete set of DNA, including all of its genes.

Science and legal experts debate future uses and impact of human genome editing in Gender & the Genome
Precise, economical genome editing tools such as CRISPR have made it possible to make targeted changes in genes, which could be applied to human embryos to correct mutations, prevent disease, or alter traits.

Evolution purged many Neanderthal genes from human genome
Neanderthal genetic material is found in only small amounts in the genomes of modern humans because, after interbreeding, natural selection removed large numbers of weakly deleterious Neanderthal gene variants, according to a study by Ivan Juric and colleagues at the University of California, Davis, published Nov.

Read More: Human Genome News and Human Genome Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to